Views & Analysis

If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed

Life sciences must become cloud-first to seize the science of tomorrow

https://pharmaphorum.com/views-analysis-digital/life-sciences-must-become-cloud-first-to-seize-the-science-of-tomorrow/

Market Access/ Views & Analysis/ Views and analysis

Pharma must adapt to embrace the opportunities of a new-look NHS

Amanda Barrell NHS, NHS market access 0 Comment

Fundamental changes to the way the NHS is structured and funded are afoot – and pharma needs to

Pharma must adapt to embrace the opportunities of a new-look NHS

https://pharmaphorum.com/views-and-analysis/pharma-must-adapt-to-embrace-the-opportunities-of-a-new-look-nhs/

Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis

Lymphoma Action – championing the patient voice in cell therapy

Susan Wormald CAR T, cell therapy, Gilead, Kite, lymphoma, Lymphoma Action, patients 0 Comment

Lymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill

Lymphoma Action – championing the patient voice in cell therapy

https://pharmaphorum.com/market-access-2/lymphoma-action-championing-the-patient-voice-in-cell-therapy/

Market Access/ Views & Analysis/ Views and analysis

2021 market access prospects for France

Leela Barham EU market access, France, HTA 0 Comment

In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes

2021 market access prospects for France

https://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-france/

Market Access/ Views & Analysis/ Views and analysis

2021 market access prospects for Spain

Leela Barham biosimilars, EU market access, Health economics, Spain 0 Comment

2021 will be the year when big market access changes – including the far wider use of health

2021 market access prospects for Spain

https://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-spain/

Market Access/ Views & Analysis/ Views and analysis

2021 market access prospects for Germany

Leela Barham AMNOG, ATMP, EU market access, Germany 0 Comment

The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG –

2021 market access prospects for Germany

https://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-germany/

Market Access/ Views & Analysis/ Views and analysis

Haven: The strategy that didn’t fix healthcare

mike.hammerton@pharmaphorum.com Amazon, Berkshire Hathaway, Haven, JP Morgan, US 0 Comment

John Singer discusses the disbanding of Haven, the joint healthcare venture by Amazon, JP Morgan and Berkshire Hathaway,

Haven: The strategy that didn’t fix healthcare

https://pharmaphorum.com/views-analysis-market-access/haven-strategy-healthcare/

Market Access/ Views & Analysis/ Views and analysis

Ireland is open: The biologics boom boosting the Irish economy

Catherine Longworth biologics, country focus, FDI, IDA Ireland, Ireland 0 Comment

The life sciences industry has an important role in the Irish economy, with sectors such as biologics booming

Ireland is open: The biologics boom boosting the Irish economy

https://pharmaphorum.com/views-analysis-market-access/ireland-is-open-the-biologics-boom-boosting-the-irish-economy/

Market Access/ Views & Analysis/ Views and analysis

Stay calm and carry on: How to implement the updated ABPI code

Amanda Barrell ABPI, ABPI code, Complimed 0 Comment

Don’t panic – that’s the message from one ABPI code expert who tells Amanda Barrell it’s time to

Stay calm and carry on: How to implement the updated ABPI code

https://pharmaphorum.com/views-analysis-market-access/how-to-implement-the-updated-abpi-code/

«‹ 6 7 8 9 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Views & Analysis

Login